2nd Wnt And B-Catenin Pathway Targeted Drug Development Summit
January 24 to January 26, 2023
Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States
With an improved understanding of biology and mechanisms of action, the Wnt/B-Catenin community is surging through clinic in 2022 with positive clinical updates. The excitement of a potential first-in-class candidate to advent combination, immuno-oncology therapies in colorectal, head and neck and non-small cell lung cancer is offering hope for patients with high unmet medical needs.
After 2 decades of research, it is now the time for drug developers to act and get together at the 2nd Wnt/B-Catenin Pathway Targeted Drug Development Summit. As the one and only industry-led meeting, you will be equipped with unparalleled insights in:
- Wnt/B-Catenin's structural biology and medicinal chemistry - turning the undruggable druggable
- Comparison of different Wnt/B-Catenin modulation approaches, its interaction with TIL and tumor microenvironment for targeted, combination therapies
- Translating basic science into clinical design - from scheduling to dosing, overcoming toxicity to widen the therapeutic window with safety in mind
- Validating a clinical biomarker for patient selection
In collaboration with Wnt/B-Catenin pioneers such as Iterion Therapeutics, Leap Therapeutics, FogPharma, this is your unique opportunity to join and meet 60+ drug developers to forge long-term collaboration and advance Wnt/B-Catenin as a valuable target and clinical asset, propelling to provide first-in-class treatments for patients!
Continue reading at nt-b-catenindrugdevelopment.com
Interested in this event?
No sessions available